This is a randomized, open-label phase II study designed to evaluate the safety and efficacy
of etoposide in patients with the 2019 novel coronavirus (COVID-19) infection. Randomization
will be performed with a 3:1 allocation ratio. Treatment will be comprised of etoposide
administered intravenously at a dose of 150 mg/m2 on Days 1 and 4 in patients with COVID-19
infection meeting eligibility criteria. Subsequent doses of etoposide will be allowed if the
investigator and treating physician believe the patient had clinical benefit from etoposide
therapy but subsequently has evidence of recurrent clinical deterioration. Subjects
randomized to control will receive standard of care treatment. No placebo will be used.